Engineering in Precision Medicine
Engineered materials that integrate advances in polymer chemistry, nanotechnology, and biological sciences have the potential to create powerful medical therapies. Dr. Khademhosseini’s group is interested in developing ‘personalized’ solutions that utilize micro- and nanoscale technolgoies to enable a range of therapies for organ failure, cardiovascular disease and cancer. In enabling this vision he works closely with clinicians (including interventional radiologists, cardiologists and surgeons). He has developed numerous techniques in controlling the behavior of patient-derived cells to engineer artificial tissues and cell-based therapies. His group also aims to engineer tissue regenerative therapeutics using water-containing polymer networks called hydrogels that can regulate cell behavior. Specifically, he has developed photo-crosslinkable hybrid hydrogels that combine natural biomolecules with nanoparticles to regulate the chemical, biological, mechanical and electrical properties of gels. These functional scaffolds induce the differentiation of stem cells to desired cell types and direct the formation of vascularized heart or bone tissues. Since tissue function is highly dependent on architecture, he has used microfabrication methods, such as microfluidics, photolithography, bioprinting, and molding, to regulate the architecture of these materials. He has employed these strategies to generate miniaturized tissues. It is anticipated that such approaches will lead to the development of next-generation regenerative therapeutics and biomedical devices.
Ali Khademhosseini is currently the CEO and Founding Director at the Terasaki Institute for Biomedical Innovation. Previously, he was a Professor of Bioengineering, Chemical Engineering and Radiology at the University of California-Los Angeles (UCLA). He joined UCLA as the Levi Knight Chair in November 2017 from Harvard University where he was Professor at Harvard Medical School (HMS) and faculty at the Harvard-MIT’s Division of Health Sciences and Technology (HST), Brigham and Women’s Hospital (BWH) and as well as associate faculty at the Wyss Institute for Biologically Inspired Engineering. At Harvard University, he directed the Biomaterials Innovation Research Center a leading initiative in making engineered biomedical materials. Dr. Khademhosseini is an Associate Editor for ACS Nano. He is a fellow of the American Institute of Medical and Biological Engineering, Biomedical Engineering Society, Royal Society of Chemistry, Biomaterials Science and Engineering, Materials Research Society, and American Association for the Advancement of Science. He is a member of the International Academy of Medical and Biological Engineering, Royal Society of Canada and Canadian Academy of Engineering. He received his Ph.D. in bioengineering from MIT (2005), and MASc (2001) and BASc (1999) degrees from University of Toronto both in chemical engineering.
Ali Khademhosseini 目前是Terasaki Institute for Biomedical Innovation的创始主任兼首席执行官。在此之前，他是加州大学洛杉矶分校（UCLA）生物工程系，化学工程系，以及放射学系的Levi Knight 讲席教授。并担任微创诊疗中心主任。他曾是哈佛大学医学院（HMS）和哈佛-麻省理工医疗科技学院（HST）终身教授，并兼职于著名的布莱根妇女医院（BWH）和Wyss研究所。 在哈佛大学，他领导创建了哈佛大学生物材料创新研究中心（BIRC）。Khademhosseini博士是ACS Nano的副主编。他拥有麻省理工学院生物工程博士学位 （2005），以及多伦多大学化学工程硕士学位（2001）和本科学位（1999）。